SCM
ARTV

Silverarc Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Silverarc Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Buy
+525,000
New +$4.78M 0.53% 51

Other funds holding ARTV

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Silverarc Capital Management's ARTV Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 525,000 shares worth $5.09M. The stake represents 0.53% of the portfolio and ranks #51 among its holdings.

38 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Silverarc Capital Management held 525,000 shares of Artiva Biotherapeutics worth $5.09M as of Q2 2026.
  • Artiva Biotherapeutics was a new Silverarc Capital Management position in Q2 2026.
  • Artiva Biotherapeutics made up 0.53% of Silverarc Capital Management's portfolio in Q2 2026, its #51 holding.
  • 38 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.